Medtronic's Cardiovascular Pipeline Fires on Two Cylinders as MiniMed Separation Nears
Published on 10/01/2026 at 15:50 | Editorial boerse-global.de
Medtronic is stacking regulatory and clinical wins in its heart business just as the company prepares to shed its diabetes unit, giving investors fresh evidence of what the slimmed-down group can do on its own.
The medtech giant's BACKBEAT pivotal trial, run with development partner Orchestra BioMed, has blown past its enrollment target. As of yesterday, 330 patients had been signed up across 81 sites in 13 countries, clearing the 316 participants originally planned. The FDA-approved protocol requires at least 284 evaluable patients to reach statistical significance, and the overshoot provides a buffer against dropouts during follow-up.
Testing a Dual-Pronged Hypertension Approach
BACKBEAT examines atrioventricular interval modulation, or AVIM, a therapy aimed at people who need a pacemaker and still have uncontrolled high blood pressure despite medication. The double-blind study randomizes participants 1:1: one arm receives AVIM alongside existing drugs and cardiac stimulation, while the control group continues with standard pacing and medication.
Investigators are tracking two primary endpoints — the change in ambulatory 24-hour blood pressure and device safety — at the three-month mark. The design is built to detect a systolic difference of at least 5 mmHg between the arms with statistical power above 90%.
Patience will be required before any of this translates into hard data. The three-month follow-up and subsequent database lock are still pending, and Orchestra BioMed and Medtronic intend to submit the primary results for a late-breaking presentation in the second quarter of 2027. Should the endpoints hold up, Medtronic plans to move swiftly with regulatory filings at the FDA and other international agencies, with commercialization contingent on those approvals.
Should investors sell immediately? Or is it worth buying Medtronic?
Fresh FDA Momentum Beyond BACKBEAT
The enrollment news lands alongside a separate burst of regulatory progress. The FDA granted breakthrough device designation yesterday for Medtronic's drug-coated IN.PACT balloon, targeting below-the-knee disease in patients with chronic limb-threatening ischemia. In near-tandem, the company secured both FDA clearance and European CE marking for its Affera Prism-2 mapping software and PulseSelect ProxBox adapter, tools designed to sharpen precision and safety during cardiac ablation procedures.
For the IN.PACT program, Medtronic is planning the IN.PACT BTK DELTA pivotal study with roughly 400 patients. Breakthrough status can speed dialogue with regulators, but it does not substitute for solid trial data — a distinction that matters as the company looks to convert these designations into revenue.
The electrophysiology arena is fiercely contested, and keeping the installed base of heart centers loyal demands a steady cadence of new mapping and adapter solutions. Delays in enrolling DELTA, clinical setbacks, or unexpected side effects in interventional vascular therapies remain persistent risks that can erode substantial upfront investment. Hesitant adoption of the new ablation systems or shipping snags would also stall momentum in that segment.
A Portfolio in Motion
All of this unfolds against a broader reshaping of the company. Medtronic announced the spinoff of its diabetes unit MiniMed about two weeks ago, a separation expected to close this month. The final exchange ratio will be determined using volume-weighted average prices from October 5 to 7, 2026, with the offer expiring on October 9, 2026 — a date that will reveal how many existing shareholders participate and how the adjusted ownership structure takes shape.
Meanwhile, Medtronic has been adding to promising areas, acquiring SPR Therapeutics, CathWorks, and Scientia Vascular this year for a combined volume of just under $1.8 billion. Management also raised its payout to shareholders, lifting the dividend for the 49th consecutive year in 2026.
Guidance for fiscal 2027, upgraded roughly three weeks ago, points to organic revenue growth of 7.25% to 7.75% and adjusted earnings per share of $5.94 to $6.00. TD Cowen reaffirmed its buy rating yesterday with a $110.00 price target, citing the group's operational momentum and management's conservative forecasting stance. If Medtronic can push toward the upper end of that range on the strength of the new products, the valuation discount to its historical band could narrow quickly.
Market Response Stays Muted
Shares barely stirred on the research milestone. The stock trades at EUR 76.12, a slight daily decline of 0.08%, giving the company a market capitalization of EUR 100.79 billion. Over the past 30 days, the equity has shed 4.0%, reflecting a market that is waiting for clearer proof of organic innovation in the remaining core business following the MiniMed move.
The road ahead hinges on execution: whether regulatory head starts can be turned into high-margin clinical sales, and whether the separation of business units proceeds without disrupting day-to-day operations. Management bandwidth is already stretched by the parallel restructuring. Should the stock stabilize at current levels and the newly cleared products roll out on schedule, the setup for a gradual advance remains in place. A shift in medtech sentiment or unexpected DELTA delays, however, could trigger another test of recent interim lows.
Ad
Medtronic Stock: New Analysis - 1 October
Fresh Medtronic information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
